On October 3, 2025 HanchorBio, a clinical-stage biotechnology company focusing on immune-oncology and dedicated to developing next-generation multi-specific immunotherapies, reported that an abstract detailing preclinical data on HCB301, the company’s novel tri-specific anti-cancer fusion protein, has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 40th Anniversary Annual Meeting (Press release, Hanchor Bio, OCT 3, 2025, View Source [SID1234656428]). The meeting will take place from November 5 to 9, 2025, in National Harbor, Maryland.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Acceptance for a poster presentation at the SITC (Free SITC Whitepaper) Annual Meeting underscores the scientific rigor and innovation behind HCB301’s development. SITC (Free SITC Whitepaper) is the world’s largest annual conference solely dedicated to cancer immunotherapy. Each year, more than 1,300 abstracts are submitted, evaluated according to rigorous selection criteria based on research quality, novelty, and their potential to advance cancer immunotherapy.
Presentation Details
The accepted abstract, titled "A Novel Tri-Specific Fc Fusion Protein Targeting PD-L1, CD47, and TGFβ Remodels the Tumor Microenvironment and Enhance Anti-Tumor Immunity", will be presented on Saturday, November 8, 2025. The presentation will highlight preclinical efficacy and safety data supporting HCB301’s potential as a first-in-class immune-enhancing biologic that targets key mechanisms of tumor immune evasion.
"We are honored to present these compelling preclinical data at SITC (Free SITC Whitepaper) 2025," said Wenwu Zhai, Chief Scientific Officer of HanchorBio. "HCB301 exemplifies the power of our FBDB platform to rationally design multi-specific biologics that restore immune activity and deliver enhanced anti-tumor responses."
About HCB301
HCB301 is a tri-functional IgG4 Fc fusion protein that incorporates:
An anti-PD-L1 antibody,
A high-affinity SIRPα variant to disrupt CD47-mediated "don’t eat me" signaling, and
A TGF-βRII trap domain.
Following successful preclinical development, HCB301 is now in a Phase 1 multi-regional clinical trial in the U.S. and Taiwan to evaluate its safety, tolerability, and anti-tumor activity in patients with advanced solid tumours.
In preclinical studies, HCB301 demonstrated:
Potent blockade of PD-L1 and TGF-β signaling,
Robust phagocytosis of CD47+ tumor cells in vitro with minimal red blood cell binding, suggesting an improved hematologic safety profile compared to CD47-targeting analogs, and
In vivo efficacy comparable to a triple-agent cocktail across multiple xenograft models.
The abstract will also be published in the Journal for ImmunoTherapy of Cancer (JITC) in February 2026 as part of the SITC (Free SITC Whitepaper) 2025 Final Supplement.